Skip to main content

NTRK1/2/3 Fusion Gene Detection

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
NTRK 1,2,3 Rearrangements in Patients With Solid TumorsN/A1 trial
Active Trials
NCT06780384Active Not Recruiting5,000Est. Aug 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerNTRK 1,2,3 Rearrangements in Patients With Solid Tumors

Clinical Trials (1)

Total enrollment: 5,000 patients across 1 trials

NCT06780384BayerNTRK 1,2,3 Rearrangements in Patients With Solid Tumors

NTRK 1,2,3 Rearrangements in Patients With Solid Tumors

Start: Feb 2020Est. completion: Aug 20255,000 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.